1. Home
  2. BHE vs MIRM Comparison

BHE vs MIRM Comparison

Compare BHE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BHE
  • MIRM
  • Stock Information
  • Founded
  • BHE 1979
  • MIRM 2018
  • Country
  • BHE United States
  • MIRM United States
  • Employees
  • BHE N/A
  • MIRM N/A
  • Industry
  • BHE Electrical Products
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • BHE Technology
  • MIRM Health Care
  • Exchange
  • BHE Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • BHE 1.7B
  • MIRM 1.9B
  • IPO Year
  • BHE 1990
  • MIRM 2019
  • Fundamental
  • Price
  • BHE $45.29
  • MIRM $41.51
  • Analyst Decision
  • BHE Strong Buy
  • MIRM Strong Buy
  • Analyst Count
  • BHE 3
  • MIRM 12
  • Target Price
  • BHE $42.33
  • MIRM $57.58
  • AVG Volume (30 Days)
  • BHE 287.4K
  • MIRM 418.0K
  • Earning Date
  • BHE 01-29-2025
  • MIRM 11-12-2024
  • Dividend Yield
  • BHE 1.50%
  • MIRM N/A
  • EPS Growth
  • BHE N/A
  • MIRM N/A
  • EPS
  • BHE 1.72
  • MIRM N/A
  • Revenue
  • BHE $2,690,572,000.00
  • MIRM $307,028,000.00
  • Revenue This Year
  • BHE N/A
  • MIRM $82.14
  • Revenue Next Year
  • BHE $4.51
  • MIRM $26.18
  • P/E Ratio
  • BHE $26.30
  • MIRM N/A
  • Revenue Growth
  • BHE N/A
  • MIRM 112.14
  • 52 Week Low
  • BHE $25.36
  • MIRM $23.14
  • 52 Week High
  • BHE $52.57
  • MIRM $48.89
  • Technical
  • Relative Strength Index (RSI)
  • BHE 36.36
  • MIRM 43.16
  • Support Level
  • BHE $45.47
  • MIRM $40.03
  • Resistance Level
  • BHE $49.06
  • MIRM $43.37
  • Average True Range (ATR)
  • BHE 1.52
  • MIRM 1.82
  • MACD
  • BHE -0.43
  • MIRM -0.51
  • Stochastic Oscillator
  • BHE 8.52
  • MIRM 22.01

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and advanced manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: